dr. L.C.L.T. (Léon) van Kempen

Molecular Pathology in general, but with a focus on melanoma, sarcoma and lung carcinoma.
Biomarker discovery and validation.
Development of diagnostic tools for clinical use.
Quality control and assurance in a clinical diagnostic environment (NEN-EN-ISO15189)

Director of Molecular Pathology, Department of Pathology, University Hospital Antwerp, Belgium (as of 01 October 2022)
EORTC melanoma group - Steering cie. and member of the pathology working group: melanomagroup.eu/site/
EORTC Pathobiology group - Work group member
Dutch Workgroup for Hematopathology (NWHP) - Steering cie member : pathology.nl/expertise-groepen/hematopathologie/
Euroclonality - Member of the quality control work group
NVVP lid expertise groep Moleculaire Pathologie
Vakinhoudelijk deskundige - Raad voor Accreditatie (RVA)
Editorial Board - Precision Cancer Medicine
Editorial Board - Cancers
Lid Stuurgroep Oncology Update Symposium
Between 2015-2022 Dr. van Kempen has received honoraria from commercial parties paid to the UMCG. Speaker fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, nanoString, Pfizer and Roche. Advisory board: Janssen-Cilag, Merck and Roche. Research funding: Amgen, Bayer, Invitae, Janssen-Cilag, MSD, nanoString and Roche